Wanna Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wanna Yang has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Guiqiang Wang
Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China
1 shared publication Jiatian Lin
Intervention and Cell Therapy Center, Peking University Shenzhen Hospital, Shenzhen Peking University-the Hong Kong University of Science and Technology Medical Center, Shenzhen 518035, Guangdong, People's Republic of China
1 shared publication- Jiyuan Zhou
Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Beijing, China
1 shared publication - Junhui Chen
Intervention and Cell Therapy Center, Peking University Shenzhen Hospital, Shenzhen, China
1 shared publication Shu Zhang
Intervention and Cell Therapy Center, Peking University Shenzhen Hospital, Shenzhen Peking University-the Hong Kong University of Science and Technology Medical Center, Shenzhen 518035, Guangdong, People's Republic of China
1 shared publicationTao Zhou
Intervention and Cell Therapy Center, Peking University Shenzhen Hospital, Shenzhen Peking University-the Hong Kong University of Science and Technology Medical Center, Shenzhen 518035, Guangdong, People's Republic of China
1 shared publication
Latest Publications
- Open Access
- 1 July 2019
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 11, 7159-7169
Diagnostic value of angiopoietin-like protein 2 for CHB-related hepatocellular carcinoma
Purpose: Angiopoietin-like protein 2 (ANGPTL2) is a secretory glycoprotein with various functions in vascular biology, inflammation and tumor development. As shown in our previous studies, ANGPTL2 expression positively correlates with liver fibrosis stages in chronic hepatitis B (CHB) patients. The aim of this study was further to assess whether ANGPTL2 represents a potential biomarker for detecting hepatocellular carcinoma (HCC). Patients and methods: This study enrolled 361 participants including healthy controls (HCs) and patients with CHB, liver cirrhosis (LC) and HCC. A discovery cohort consisted of 35 HCs and 55 patients with HCC. A total of 271 participants, including 45 HCs, 125 patients with CHB, 38 patients with LC, and 63 patients with HCC were enrolled in a validation cohort. Serum ANGPTL2 levels were detected using a human ANGPTL2 assay kit, and hepatic expression of ANGPTL2 was analyzed using immunohistochemistry. Results: In the discovery cohort, a significantly higher serum ANGPTL2 level was detected in HCC than in HCs (73.49±33.87 vs 30.54±9.86; pConclusions: ANGPTL2 may be used as a promising biomarker for the diagnosis of CHB-related HCC.
- 1 July 2019
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 11, 7159-7169
Open AccessDiagnostic value of angiopoietin-like protein 2 for CHB-related hepatocellular carcinoma
Purpose: Angiopoietin-like protein 2 (ANGPTL2) is a secretory glycoprotein with various functions in vascular biology, inflammation and tumor development. As shown in our previous studies, ANGPTL2 expression positively correlates with liver fibrosis stages in chronic hepatitis B (CHB) patients. The aim of this study was further to assess whether ANGPTL2 represents a potential biomarker for detecting hepatocellular carcinoma (HCC). Patients and methods: This study enrolled 361 participants including healthy controls (HCs) and patients with CHB, liver cirrhosis (LC) and HCC. A discovery cohort consisted of 35 HCs and 55 patients with HCC. A total of 271 participants, including 45 HCs, 125 patients with CHB, 38 patients with LC, and 63 patients with HCC were enrolled in a validation cohort. Serum ANGPTL2 levels were detected using a human ANGPTL2 assay kit, and hepatic expression of ANGPTL2 was analyzed using immunohistochemistry. Results: In the discovery cohort, a significantly higher serum ANGPTL2 level was detected in HCC than in HCs (73.49±33.87 vs 30.54±9.86; pConclusions: ANGPTL2 may be used as a promising biomarker for the diagnosis of CHB-related HCC.